Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2000

View Archived Issues

Onyvax begins clinical trials for colorectal cancer vaccines

Nerve growth factor related to increased irritant sensitivity in allergic rhinitis

AVI BioPharma demonstrates promise of new telomerase inhibitor

Maret initiates second clinical trial with MARstem

FDA approval of Targis System Express Protocol shortens treatment time

Connetics reports positive phase II clinical data for treatment of scleroderma

Encouraging preclinical results for NCX-701

Adenosine Therapeutics enters license agreement for adenosine receptor antagonists

Discovery of VX-740/HMR-3480 detailed by Vertex at recent scientific meeting

Agouron and PPD Discovery create anticancer genomics alliance

Calyx adds CLX-0921 and CLX-0940 to the development pipeline

Ligand makes milestone payment to Elan for Morphelan NDA submission

U.S. District Court hands down favorable ruling for Pfizer in trademark suit

Prevention of diabetes in mice by administration of novel interferon

Micrologix and Harbor-UCLA to codevelop antibiotics for drug-resistant infections

Ligand receives approvable letter from FDA for Targretin Gel

SPM-962 safe and clinically effective in PD according to data presented at Barcelona meeting

ADA news: glycogen phosphorylase inhibitor displays hypoglycemic and cardioprotective effects

Chronic oral treatment with DP IV inhibitor P-32/98 provides good metabolic control in diabetic rats

Novel IK(Ca) channel inhibitor presented at ASBMB/ASPET 2000 by UCI

Potent and selective human red blood cell IK(Ca) channel blockers reported at ASBMB/ASPET

Antihypertensive combination of lacidipine and telmisartan superior to monotherapies

Lilly describes new group of metabotropic glutamate receptor modulators and their use

Potent new MMP inhibitor series patented by ADIR

Metalloporphyins and their use as antibacterial agents reported by Emory U.

Fungally produced compound active against human tumor cell lines

Synthesis, activity and use of new inhibitors of protein farnesyltransferase

Merck presents new inhibitors of Kv1.3 and Kv1.5 channels

Selective iNOS inhibitors in early development at the newly formed Pharmacia

Antibacterial agents designed at Hokuriku effective against Gram-positive bacteria and mycobacteria

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment
BioWorld Science
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR)...